Syneron Medical Ltd. (NASDAQ:ELOS) shares saw an uptick in trading volume on Monday . 67,386 shares traded hands during trading, an increase of 20% from the previous session’s volume of 56,075 shares.The stock last traded at $7.34 and had previously closed at $7.37.

A number of research firms have recently weighed in on ELOS. Zacks Investment Research raised Syneron Medical from a “sell” rating to a “hold” rating in a report on Monday, July 25th. Brean Capital reaffirmed a “buy” rating on shares of Syneron Medical in a research note on Thursday, June 16th.

The company’s 50-day moving average price is $7.34 and its 200-day moving average price is $7.18. The company’s market capitalization is $254.34 million.

Syneron Medical (NASDAQ:ELOS) last announced its quarterly earnings data on Thursday, May 19th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The business earned $68.70 million during the quarter, compared to the consensus estimate of $64.38 million. During the same quarter last year, the company earned $0.02 EPS. The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. On average, analysts expect that Syneron Medical Ltd. will post $0.27 EPS for the current year.

Other hedge funds and institutional investors have made changes to their positions in the company. Royce & Associates LLC increased its position in shares of Syneron Medical by 7.2% in the fourth quarter. Royce & Associates LLC now owns 663,159 shares of the company’s stock worth $5,113,000 after buying an additional 44,700 shares during the period. Lapides Asset Management LLC increased its position in shares of Syneron Medical by 210.4% in the fourth quarter. Lapides Asset Management LLC now owns 237,800 shares of the company’s stock worth $1,833,000 after buying an additional 161,200 shares during the period. Finally, Brandes Investment Partners LP increased its position in shares of Syneron Medical by 206.1% in the fourth quarter. Brandes Investment Partners LP now owns 1,745,669 shares of the company’s stock worth $13,459,000 after buying an additional 1,175,299 shares during the period.

Syneron Medical Ltd. is engaged in manufacture, research, development, marketing and sales of advanced equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company designs, develops and markets aesthetic medical products based on its various technologies, including Electro-Optical Synergy (ELOS) technology to provide aesthetic medical treatments.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.